At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other stocks Jim Cramer recently discussed. In a recent episode of CNBC's Squawk On The Street ...

CEO Albert Bourla said the company’s dispute with activist firm Starboard Value isn’t “an aggressive situation,” months after the ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

From condemning the Jan. 6 Capitol riots to helping fund the President-elect’s impending inauguration, recent years have seen ...

U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other stocks Jim Cramer recently discussed. In a recent episode of CNBC's Squawk On The Street, Jim ...